Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Depression & anxiety in the primary care setting

L A Cunningham1

  • 1Vine Street Clinical Research Center Springfield, Illinois 62701, USA.

Comprehensive Therapy
|June 1, 1997
PubMed
Summary

For depression and anxiety, newer antidepressants are generally safe choices when diagnosis is uncertain. While anxiety disorders respond well to antidepressants, depression does not respond to tranquilizers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tissue inhibitor of metalloproteinases-3 facilitates Fas-mediated neuronal cell death following mild ischemia.

Cell death and differentiation·2007
Same author

Vulnerability of mouse cortical neurons to doxorubicin-induced apoptosis is strain-dependent and is correlated with mRNAs encoding Fas, Fas-Ligand, and metalloproteinases.

Apoptosis : an international journal on programmed cell death·2004
Same author

Tissue inhibitor of metalloproteinases-3 and matrix metalloproteinase-3 regulate neuronal sensitivity to doxorubicin-induced apoptosis.

The European journal of neuroscience·2003
Same author

Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures.

Brain research·2001
Same author

Coupling of AMPA receptors with the Na(+)/Ca(2+) exchanger in cultured rat astrocytes.

Brain research·2001
Same author

Glial cell line-derived neurotrophic factor in the rat pituitary gland.

Brain research bulletin·2000

Area of Science:

  • Primary Care Medicine
  • Psychiatry
  • Clinical Pharmacology

Background:

  • Depression and anxiety disorders are prevalent in primary care settings.
  • Accurate diagnosis relies on specific criteria, such as those in the DSM-IV.
  • Differential diagnosis can be challenging.

Purpose of the Study:

  • To provide guidance on the pharmacological management of depression and anxiety disorders in primary care.
  • To differentiate treatment responses to various psychotropic medications.
  • To offer recommendations for drug selection when diagnostic uncertainty exists.

Main Methods:

  • Review of diagnostic criteria for depression and anxiety disorders.
  • Analysis of treatment efficacy for different drug classes, including antidepressants, tranquilizers, benzodiazepines (BZ), and azapirones.
  • Discussion of medication use in specific conditions like generalized anxiety disorder and mixed anxiety-depression.

Main Results:

  • Antidepressant medications are the primary treatment for both depression and anxiety disorders.
  • Anxiety disorders respond well to most antidepressants, but depression does not respond to tranquilizers.
  • Benzodiazepines (BZ) are best used as adjunctive therapy in early treatment stages.
  • Buspirone is effective as a first-line treatment for generalized anxiety disorder and can augment antidepressants for mixed anxiety-depression.

Conclusions:

  • When in doubt regarding diagnosis or initial drug choice for depression or anxiety, newer antidepressants are a generally safe option.
  • Pharmacological management requires careful consideration of the specific disorder and patient presentation.
  • Understanding differential treatment responses is crucial for effective patient care.

Related Experiment Videos